0001209191-21-016973.txt : 20210303 0001209191-21-016973.hdr.sgml : 20210303 20210303170132 ACCESSION NUMBER: 0001209191-21-016973 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210302 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McFarlane Neil F. CENTRAL INDEX KEY: 0001681098 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 21710126 MAIL ADDRESS: STREET 1: C/O RETROPHIN, INC. STREET 2: 12255 EL CAMINO REAL, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-02 0 0001328143 Adamas Pharmaceuticals Inc ADMS 0001681098 McFarlane Neil F. C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 0 1 0 0 Chief Executive Officer Common Stock 2021-03-02 4 A 0 300000 0.00 A 525000 D The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/3rd of the total number of Restricted Stock Units will vest on each of March 1, 2022, March 1, 2023 and March 1, 2024, subject to Reporting Person's Continuous Service as of each such date. /s/ Christopher B. Prentiss, Attorney-in-fact 2021-03-03